drugset / Trial / NCT03427060
Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms
NaSingle-groupOpen-labelTreatment
Summary
Coversin in Paroxysmal Nocturnal Hemoglobinuria (PNH) in patients with resistance to Eculizumab due to complement C5 polymorphisms.
Timeline
- Start
- 2018-05-14
- Primary completion
- 2018-11-15
- Completion
- 2021-02-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Coversin | Protein / enzyme biologic | 45 mg | Subcutaneous |